Description
Doxazosin mesylate is a selective alpha, blocker indicated for the treatment of
hypertension, reportedly of special benefit as a first-line agent in the most hypertonic
patient population. Another advantage of doxazosin is its favorable effect on blood lipids;
it significantly increases the HDL/total cholesterol ratio and decreases the total cholesterol
as well as triglycerides levels.
Originator
Pfizer (United Kingdom)
Uses
ACIPHEX therapeutic Erosive or Ulcerative Gastroesophageal Reflux Disease
Definition
ChEBI: A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl
roup at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Brand name
Cardura (Pfizer);Carduran.
General Description
Doxazosin, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazine(Cardura), is a quinazoline compound that selectively inhibitsthe α1-subtype of α-adrenergic receptors. This agentis very useful in the management of hypertension associatedwith pheochromocytoma.
Clinical Use
Alpha-adrenoceptor blocker:
Hypertension
Benign prostatic hyperplasia (BPH)
Drug interactions
Potentially hazardous interactions with other drugs
Antidepressants: enhanced hypotensive effect with
MAOIs.
Avanafil, vardenafil, sildenafil and tadalafil: enhanced
hypotensive effect, avoid with tadalafil, start the
others at the lowest possible dose.
Beta-blockers: enhanced hypotensive effect;
increased risk of first dose hypotensive effect.
Calcium-channel blockers: enhanced hypotensive
effect, increased risk of first dose hypotensive effect.
Diuretics: enhanced hypotensive effect, increased risk
of first dose hypotensive effect.
Moxisylyte: possibly severe postural hypotension
when used in combination.
Metabolism
Doxazosin is extensively metabolised in the liver,
and excreted in faeces as inactive metabolites
(6-hydroxydoxazosin) and a small amount of unchanged
drug
